Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System (Yale-HF)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04237701 |
Recruitment Status :
Recruiting
First Posted : January 23, 2020
Last Update Posted : July 14, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Heart Failure Heart Failure With Reduced Ejection Fraction Heart Failure With Preserved Ejection Fraction Heart Failure NYHA Class IV |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 40000 participants |
Observational Model: | Cohort |
Time Perspective: | Other |
Target Follow-Up Duration: | 10 Years |
Official Title: | Retrospective and Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System Via a Live Registry |
Actual Study Start Date : | October 1, 2019 |
Estimated Primary Completion Date : | December 30, 2025 |
Estimated Study Completion Date : | December 30, 2025 |

- Number of participants hospitalized for heart failure [ Time Frame: 10 years ]Heart Failure hospitalizations
- Doses of therapies that comprise guideline directed medical therapy [ Time Frame: 10 years ]Appropriate use of guideline recommended therapies. This will include doses of beta blockers, ACE inhibitors, ARBs, ARNI, SGLT2i, ICD use.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Seen within the Yale New Haven Health System
- Diagnosis of heart failure
Exclusion Criteria:
- Age<18

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04237701
Contact: Tariq Ahmad, MD MPH | (203) 843-1667 | Tariq.ahmad@yale.edu | |
Contact: Nihar Desai, MD MPH | 203-767-6399 |
United States, Connecticut | |
Yale New Haven Health System | Recruiting |
New Haven, Connecticut, United States, 06510 | |
Contact: Tariq Ahmad, MD MPH 203-843-1667 tariq.ahmad@yale.edu | |
Contact: Nihar Desai, MD MPH 2037676399 nihar.desai@yale.edu | |
Principal Investigator: Tariq Ahmad, MD MPH | |
Principal Investigator: Nihar Desai, MD MPH |
Study Director: | Nihar Desai, MD MPH | Yale University | |
Principal Investigator: | Tariq Ahmad, MD MPH | Yale University |
Responsible Party: | Yale University |
ClinicalTrials.gov Identifier: | NCT04237701 |
Other Study ID Numbers: |
2000026771 |
First Posted: | January 23, 2020 Key Record Dates |
Last Update Posted: | July 14, 2021 |
Last Verified: | July 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Data is on patients seen at Yale New Haven Health system and will be used for quality improvement. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Heart Failure Heart Diseases Cardiovascular Diseases |